Cargando…
Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC
INTRODUCTION: The development of a new type of Thymidylate synthase (TS) inhibitor that could inhibit cancer cells' proliferation and anti-angiogenesis is of great significance for cancer's clinical treatment. OBJECTIVES: Our research hopes to develop a TS inhibitor that is more effective...
Autores principales: | Li, Xin-yang, Wang, De-pu, Lu, Guo-qing, Liu, Kai-li, Zhang, Ting-jian, Li, Shuai, Mohamed O, Kamara, Xue, Wen-han, Qian, Xin-hua, Meng, Fan-hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584679/ https://www.ncbi.nlm.nih.gov/pubmed/33133686 http://dx.doi.org/10.1016/j.jare.2020.07.008 |
Ejemplares similares
-
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007) -
Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity
por: Li, Xin-yang, et al.
Publicado: (2019) -
Targeting Methyltransferases in Human Pathogenic Bacteria: Insights into Thymidylate Synthase (TS) and Flavin-Dependent TS (FDTS)
por: Pozzi, Cecilia, et al.
Publicado: (2019) -
The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition
por: Webley, S D, et al.
Publicado: (2001) -
P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting
por: Gokare, Prashanth, et al.
Publicado: (2017)